| Abstract: |
Endometrial cancer has moved from being a histologic diagnosis alone to one that also considers the molecular classification of the tumor. Molecular classification is not only feasible but highly recommended because it improves the diagnostic classification and provides prognostic information that may guide treatment. The NCCN Cervical/Uterine Cancers Guidelines recognize the novel approach proposed by FIGO, but has concerns about the 2023 FIGO staging system and therefore does not recommend its use by clinicians. Advances in systemic treatment, particularly the introduction of immunotherapy, has greatly improved outcomes in endometrial cancer, especially for patients with mismatch repair-deficient tumors. |
